AMN Healthcare's second quarter is the cleanest evidence yet that the post-pandemic travel-nurse downcycle has bottomed, but the print is also a textbook case of why headline numbers can mislead. Revenue of $673 million rose a modest 2% year over year, yet reported GAAP diluted earnings per share swung to a $0.53 profit from a $3.02 loss a year ago, the apparent turnaround driven almost entirely by the absence of two non-cash impairment charges ($109.5 million of goodwill plus $18.3 million of long-lived asset writedowns) that crushed the prior-year quarter. Strip those out and the underlying story is more nuanced: adjusted diluted EPS of $0.77 beat year-ago $0.30 by a wide margin because the underlying franchise is genuinely healthier, but the sequential collapse is the real cautionary tale, with consolidated revenue down 51% from the first quarter because a $722 million labor-disruption booking in Q1 did not repeat.
We see this as the most important read of the quarter. The travel-nurse and allied franchises, the heart of the company's cyclical exposure, are stabilizing for a second consecutive quarter. Travel-nurse revenue grew 10% year over year and allied revenue grew 8%, which is the directional signal the market has been waiting for since the post-pandemic bill-rate compression started in mid-2023. The single load-bearing risk is that the labor-disruption line item, which produced $722 million in Q1 and only $25 million in Q2, normalizes the headline trajectory in a way that obscures the underlying recovery; without the disruption tailwind, year-to-date revenue actually grew 52%, and the Q1-over-Q1 comparability is now broken in a way the third-quarter guide has to absorb.
The falsifiable clock is the third-quarter print, where management has guided consolidated revenue of $640 million to $655 million (only 1% to 3% year-over-year growth) with adjusted EBITDA margin of 6.5% to 7.0%. That margin guide is roughly 400 basis points below the second quarter's 10.9%, and the delta is the cleanest possible test of whether the gross-margin expansion in Q2 was a structural travel-nurse recovery or a one-time benefit from labor-disruption reserve releases and billing true-ups. A third-quarter adjusted EBITDA margin above 8% would confirm the structural read; a print below 6.5% would re-open the question of whether the underlying demand environment is genuinely healing or whether the Q2 print was a fiscal-distortion artifact.